Alexza Pharmaceuticals, Inc. (ALXA) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 14 PAGES: 49

More Info
									            Alexza Pharmaceuticals, Inc. (ALXA) - Financial and Strategic SWOT
                                     Analysis Review
        Reference Code: GDPH17617FSA                                                                                          Publication Date: MAR 2012

          2091 Stierlin Court                                Phone              +1 650 9447000                  Revenue          42.9 (million USD)
          MOUNTAIN VIEW, CA                                  Fax                +1 650 9447999                  Net Profit       -40.53 (million USD)
          94043                                              Website            www.alexza.com                  Employees        97
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           ALXA [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Alexza Pharmaceuticals, Inc. (Alexza), formerly Alexza Molecular Delivery Corp., is a specialty pharmaceutical company. The
       company carries out the research and development and commercializes novel proprietary products used for the acute treatment
       of central nervous system diseases. The company develops all its products based on its own proprietary technology, Staccato
       system. The product candidate's that the company offers includes ADASUVE (Staccato loxapine), AZ-104 (Staccato loxapine),
       AZ-003 (Staccato fentanyl), AZ-002 (Staccato alprazolam), AZ-007 (Staccato zaleplon) and Staccato nicotine (Preclinical).
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Alexza Pharmaceuticals, Inc., SWOT Analysis
         Thomas B. King                      Chief Executive Officer                  Strengths                              Weaknesses
         Hal V. Barron, M.D.                 Director
                                                                                      Intellectual Property                  History of Losses
         Samuel D. Colella                   Director
                                                                                      Unique Staccato Technology             Reliance on Third Parties
         Alan D. Frazier                     Director
         Deepika R. Pakianathan, Director
         Ph.D.                                                                        Opportunities                          Threats
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Promising Product Pipeline             Non-compliance of Government
                                                                                                                             Regulations
       Share Data                                                                     Partnership with Grupo Ferrer
                                                                                                                             Uncertain R&D Outcomes
         Alexza Pharmaceuticals, Inc.
                                                                         0.62
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                       -0.60        GlobalData
        Market Cap (million USD)                                          0.0
        Enterprise Value (million USD)                                    NA
        Shares Outstanding (million)                                     116
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 12, 2012         Alexza Pharmaceuticals Reports Revenue Of
                                                                                                           $1.9m In Q4 2011
                                                                                      Dec 16, 2011         Alexza Retains Lazard To Explore Strategic
                                                                                                           Options
                                                                                      Nov 07, 2011         Alexza Pharmaceuticals Reports Revenue Of
                                                                                                           $1.3m In Q3 2011
                                                                                      Aug 08, 2011         Alexza Reports Total Revenue Of $1.3m For
                                                                                                           Q2 2011
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Alexza Pharmaceuticals, Inc. (ALXA) - Financial and Strategic                                                                  Reference Code: GDPH17617FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Alexza Pharmaceuticals, Inc. - Key Facts .......................................................................................................................................... 5
       Alexza Pharmaceuticals, Inc. - Key Employees ................................................................................................................................. 6
       Alexza Pharmaceuticals, Inc. - Key Employee Biographies ............................................................................................................... 7
       Alexza Pharmaceuticals, Inc. - Major Products and Services............................................................................................................. 8
       Alexza Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data ............................................................................................ 9
          Alexza Pharmaceuticals, Inc., Pipeline Products by Therapy Area................................................................................................. 9
          Alexza Pharmaceuticals, Inc., Pipeline Products by Development Phase .................................................................................... 10
       Alexza Pharmaceuticals, Inc. - Medical Equipment Pipeline Products Data..................................................................................... 12
          Alexza Pharmaceuticals, Inc. Pipeline Products by Equipment Type ........................................................................................... 12
          Alexza Pharmaceuticals, Inc. Pipeline Products by Development Stage ...................................................................................... 14
       Alexza Pharmaceuticals, Inc. - History ............................................................................................................................................. 16
       Alexza Pharmaceuticals, Inc. - Company Statement........................................................................................................................ 18
       Alexza Pharmaceuticals, Inc. - Locations And Subsidiaries ............................................................................................................. 22
          Head Office ................................................................................................................................................................................... 22
          Other Locations & Subsidiaries ..................................................................................................................................................... 22
       Section 2 – Company Analysis ......................................................................................................................................................... 23
       Alexza Pharmaceuticals, Inc. - Business Description ....................................................................................................................... 23
       Alexza Pharmaceuticals, Inc. - Corporate Strategy .......................................................................................................................... 24
       Alexza Pharmaceuticals, Inc. - SWOT Analysis ............................................................................................................................... 25
          SWOT Analysis - Overview........................................................................................................................................................... 25
          Alexza Pharmaceuticals, Inc. - Strengths ..................................................................................................................................... 25
             Strength - Intellectual Property .................................................................................................................................................. 25
             Strength - Unique Staccato Technology .................................................................................................................................... 25
             Strength - Focused Research and Development Activities ....................................................................................................... 25
          Alexza Pharmaceuticals, Inc. - Weaknesses ................................................................................................................................ 25
             Weakness - History of Losses ................................................................................................................................................... 25
             Weakness - Reliance on Third Parties ...................................................................................................................................... 26
          Alexza Pharmaceuticals, Inc. - Opportunities ............................................................................................................................... 26
             Opportunity - Promising Product Pipeline.................................................................................................................................. 26
             Opportunity - Partnership with Grupo Ferrer ............................................................................................................................. 26
             Opportunity - Market Potential – Central Nervous System ........................................................................................................ 26
          Alexza Pharmaceuticals, Inc. - Threats......................................................................................................................................... 27
             Threat - Non-compliance of Government Regulations .............................................................................................................. 27
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 27
             Threat - Cost Containment Pressures ....................................................................................................................................... 27
             Threat - Competitive Pressures ................................................................................................................................................. 27
       Alexza Pharmaceuticals, Inc. - Key Competitors .............................................................................................................................. 29
       Section 3 – Company Financial Ratios ............................................................................................................................................. 30
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 30
       Performance Chart ........................................................................................................................................................................... 32
       Financial Performance...................................................................................................................................................................... 32


Alexza Pharmaceuticals, Inc. (ALXA) - Financial and Strategic                                                                                                  Reference Code: GDPH17617FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report i
								
To top